CHARACTERIZATION OF RECOMBINANT EXTRACELLULAR DOMAIN OF HUMAN INTERLEUKIN-10 RECEPTOR

被引:54
|
作者
TAN, JC [1 ]
BRAUN, S [1 ]
RONG, H [1 ]
DIGIACOMO, R [1 ]
DOLPHIN, E [1 ]
BALDWIN, S [1 ]
NARULA, SK [1 ]
ZAVODNY, PJ [1 ]
CHOU, CC [1 ]
机构
[1] SCHERING PLOUGH CORP,RES INST,DEPT IMMUNOL,KENILWORTH,NJ 07033
关键词
D O I
10.1074/jbc.270.21.12906
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The extracellular region of the human interleukin-10 (hIL-10) receptor was expressed using a myeloma cell line and was purified to homogeneity by Ligand-affinity chromatography. SDS-polyacrylamide gel electrophoresis analysis indicated that the soluble receptor is glycosylated and has an apparent molecular mass of 35,000-45,000. Under native conditions, soluble hIL-10 receptor was determined by gel filtration to be a monomeric protein. Soluble hIL-10 receptor was able to inhibit the binding of I-125-hTL-10 to the full-length receptor and was able to antagonize the effect of human IL-10 in cell proliferation and cytokine synthesis inhibition. The apparent dissociation constant (K-d) of soluble hIL-10 receptor was determined to be 563 +/- 59 pM, approximately 2- to 10-fold higher than that found on intact cells (Tan, J. C., Idelicato, S. R., Narula, S. IL, Zavodny, P. J., and Chou, C.-C. (1993) J. Biol. Chem. 268, 21053-21059; Liu, Y., Wei, S. H.-Y., Ho, A S.-Y., de Waal Malefyt, R., and Moore, IL m. (1994) J. Immunol. 152, 1821-1829). When hIL-10 binds soluble hIL-10 receptor in solution, a single complex was detected by gel filtration, and the complex was found to consist of two hIL-10 dimers and four soluble receptor monomers, suggesting that hIL-10 may induce a novel mode of oligomerization of the receptor upon binding.
引用
收藏
页码:12906 / 12911
页数:6
相关论文
共 50 条
  • [1] Interleukin-10 and the interleukin-10 receptor
    Moore, KW
    Malefyt, RD
    Coffman, RL
    O'Garra, A
    ANNUAL REVIEW OF IMMUNOLOGY, 2001, 19 : 683 - 765
  • [2] Interleukin-10 and interleukin-10 receptor in human osteoarthritic and healthy chondrocytes
    Iannone, F
    De Bari, C
    Dell'Accio, F
    Covelli, M
    Cantatore, FP
    Patella, V
    Lo Bianco, G
    Lapadula, G
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2001, 19 (02) : 139 - 146
  • [3] Pharmacokinetics and Leukocyte Responses of Recombinant Human Interleukin-10
    Elaine Radwanski
    Abhijit Chakraborty
    Scott Van Wart
    Richard D. Huhn
    David L. Cutler
    Melton B. Affrime
    William J. Jusko
    Pharmaceutical Research, 1998, 15 : 1895 - 1901
  • [4] Preclinical safety evaluation of recombinant human interleukin-10
    Rosenblum, LY
    Johnson, RC
    Schmahai, TJ
    REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2002, 35 (01) : 56 - 71
  • [5] Pharmacokinetics and leukocyte responses of recombinant human interleukin-10
    Radwanski, E
    Chakraborty, A
    Van Wart, S
    Huhn, RD
    Cutler, DL
    Affrime, MB
    Jusko, WJ
    PHARMACEUTICAL RESEARCH, 1998, 15 (12) : 1895 - 1901
  • [6] Mapping of the interleukin-10/interleukin-10 receptor combining site
    Reineke, U
    Sabat, R
    Volk, HD
    Schneider-Mergener, J
    PROTEIN SCIENCE, 1998, 7 (04) : 951 - 960
  • [7] INTERLEUKIN-10 RECEPTOR - DETECTION AND CHARACTERIZATION ON HUMAN AND MOUSE-CELL LINES
    CHOU, CC
    TAN, J
    INDELICATO, S
    NARULA, SK
    ZAVODNY, PJ
    FASEB JOURNAL, 1993, 7 (07): : A1112 - A1112
  • [8] FUNCTIONAL REGIONS OF THE MOUSE INTERLEUKIN-10 RECEPTOR CYTOPLASMIC DOMAIN
    HO, ASY
    WEI, SHY
    MUI, ALF
    MIYAJIMA, A
    MOORE, KW
    MOLECULAR AND CELLULAR BIOLOGY, 1995, 15 (09) : 5043 - 5053
  • [9] Recombinant human interleukin-10 in patients with chronic myelomonocytic leukemia
    Sophie Pöchlauer
    Eva Jäger
    Ulrich Jäger
    Klaus Geissler
    Annals of Hematology, 2014, 93 : 1775 - 1776
  • [10] Recombinant human interleukin-10 in patients with chronic myelomonocytic leukemia
    Poechlauer, S.
    Jaeger, E.
    Jaeger, U.
    Geissler, K.
    ONKOLOGIE, 2013, 36 : 241 - 241